The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · May 2021
Durability and clinical experience using a bovine pericardial prosthetic aortic valve.
To report the implant experience and long-term outcomes from a large tertiary care referral center on surgical aortic valve replacement (SAVR) with a contemporary stented pericardial bioprosthesis with anticalcification treatment. ⋯ Outcomes from this large single-center cohort at increased surgical risk demonstrate excellent long-term durability of the Trifecta valve for SAVR and feasibility of treating SVD by V-in-V TAVI.
-
J. Thorac. Cardiovasc. Surg. · May 2021
Experience with porcine beating heart simulator for coronary artery bypass surgery residency training.
To evaluate the effect of our uniquely designed beating heart simulator for coronary artery bypass surgery residency training. ⋯ The effect of our uniquely developed beating heart simulator training was better than those of nonbeating heart simulator for OPCABG and ONCABG training of surgeons during residency.
-
J. Thorac. Cardiovasc. Surg. · May 2021
Transplantation of viable mitochondria attenuates neurologic injury after spinal cord ischemia.
Spinal cord ischemia (SCI) is one of the major concerns of postoperative paraplegia during major vascular or aortic surgery. Since mitochondrial dysfunction develops at the early stage of SCI, this study tested the neuronal protective effect of transplantation of viable mitochondria to the ischemic cord in rats. ⋯ Our study showed that transplantation of freshly isolated mitochondria during the early stage of spinal cord ischemia-reperfusion injury suppressed the oxidative stress in endoplasmic reticulum of the injured cord, thereby reducing neuroapoptosis and improving locomotor function of rats with SCI.
-
J. Thorac. Cardiovasc. Surg. · May 2021
A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion.
To determine the dose-limiting toxicity of oxaliplatin chemotherapy delivered by in vivo lung perfusion (IVLP). To allow assessment of subacute toxicities, we aimed to develop a 72-hour porcine IVLP survival model. ⋯ A stable and reproducible porcine 3-day IVLP survival model was established that will allow toxicity assessment of agents delivered by IVLP. Oxaliplatin delivered by IVLP showed delayed-onset toxicity that was not apparent at the time of reperfusion, with a maximal-tolerated dose of 40 mg/L. This information will inform initiation of a clinical trial examining IVLP delivery of oxaliplatin at our institution.